Last reviewed · How we verify
Naltexone
Naltrexone, marketed by the Finnish Institute for Health and Welfare, is an established drug with a key composition patent expiring in 2028. Its primary strength lies in its well-established market presence and long-term use. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Naltexone |
|---|---|
| Sponsor | Finnish Institute for Health and Welfare |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Oral vs. Injectable Naltrexone for Hospitalized Veterans With Alcohol Dependence (PHASE3)
- Comparative Trial Of Disulfiram, Naltrexone And Acamprosate In The Treatment Of Alcohol Dependence (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naltexone CI brief — competitive landscape report
- Naltexone updates RSS · CI watch RSS
- Finnish Institute for Health and Welfare portfolio CI